Biosimilar Development Strategy

Biosimilar Development Strategy designates the comprehensive scientific, regulatory, and commercial planning framework guiding development of biologic medicines demonstrated to be highly similar to an approved reference biologic, encompassing analytical similarity programmes, nonclinical and clinical data packages, regulatory submissions, and market positioning approaches.

The biopharmaceutical industry develops biosimilar strategies through stepwise totality-of-evidence approaches. Extensive analytical characterisation comparing structural, physicochemical, and functional attributes to the reference product forms the foundation. Residual uncertainty identified through analytical comparison guides the extent of required nonclinical and clinical studies. Regulatory interactions early in development align programme design with agency expectations across target markets. Commercial strategies address reference product intellectual property, manufacturing cost optimisation, and market positioning relative to the originator and other biosimilar competitors. As biosimilar markets mature and competitive dynamics intensify, development efficiency through platform approaches and regulatory pathway optimisation continues improving the commercial viability of biosimilar programmes.